Technology
Health
Biotechnology

Vaccinex

$6.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-2.06%) Today
-$0.25 (-3.76%) After Hours

Why Robinhood?

You can buy or sell Vaccinex and other stocks, options, ETFs, and crypto commission-free!

About

Vaccinex, Inc. Common Stock, also called Vaccinex, is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Read More Te firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline include SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Employees
44
Headquarters
Rochester, New York
Founded
1997
Market Cap
77.92M
Price-Earnings Ratio
Dividend Yield
Average Volume
16.69K
High Today
$6.65
Low Today
$6.65
Open Price
$6.65
Volume
1.00
52 Week High
$12.00
52 Week Low
$3.32

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2018 IPO
US
North America

News

Seeking AlphaMay 15

Vaccinex reports Q1 results

Vaccinex (NASDAQ:VCNX): Q1 Revenue of $0.09M (-55.0% Y/Y) Cash and cash equivalents and marketable securities of $11.3M. Press Release...

31

Earnings

-$1.62
-$1.33
-$1.04
-$0.75
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.75 per share
Actual
-$0.79 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.